Market Cap
$1.5M
CDT
CDT Equity Inc.
$0.9900 ▼ -20.80%
Prev close $1.25Market cap$1.5M
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on CDT right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
1 funds
Inst. Value
$10.00
Insider Activity
$0.00 buy / $2.9M sell
Insider Net $
-$2.9M
Social Sentiment
47° Neutral
SEC Reports
6
Press Releases
2
Price chart 30d -94.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 trading_halt
Sep 1, 2026 SEC Halt Resumed: CDT — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-28T23:50:00.000Z | Resumed 2026-09-29T13:00:00.000Z
CDT Equity Inc. appointed James Bligh as CEO, replacing Dr. Andrew Regan who resigned immediately. Bligh, who also remai
8-K — Impact 6/10
Aug 28, 2026 Insider
Regan Andrew acquired via exercise 5,436,830 shares
Chief Executive Officer @ $0.000100 ($543.68)
Aug 28, 2026 Insider
Regan Andrew sold 290 shares
Chief Executive Officer
Aug 28, 2026 Insider
Jul 31, 2026 SEC Regan Andrew acquired 5,436,830 shares
Chief Executive Officer
CDT Equity Inc. acquired 270 shares of Sarborg Limited (4.76% stake) in exchange for issuing pre-funded warrants to purc
8-K — Impact 8/10
CDT Equity Inc. filed a 1-for-10 reverse stock split to maintain compliance with Nasdaq's minimum bid-price rule, effect
8-K — Impact 5/10
CDT Equity announced that AZD5904, a myeloperoxidase inhibitor licensed from AstraZeneca, has entered the PCT phase for
Impact 4/10
Social media sentiment mood +25.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
47°
Neutral
BearishNeutralBullish
Recent posts
$CDT
▲ 1 · 💬 0· ⚡ 0.5
So do I cover at 7pm CDT or let it ride???
▲ 1 · 💬 7· ⚡ 0.5
22 JUNE 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?
▲ 1 · 💬 1· ⚡ 0.5
$CDT Monday run?
▲ 1 · 💬 1· ⚡ 0.5
CDT doubled premarket on a quantum-computing headline that isn't really its own, then gave it all back
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 5 bearish, 0 mixed, 0 neutral · avg impact 6.7/10.Plus 2 press releases.
BEARISH8-K6/10
CDT Equity Inc. appointed James Bligh as CEO, replacing Dr. Andrew Regan who resigned immediately. B
Sep 1, 2026
BEARISH8-K8/10
CDT Equity Inc. acquired 270 shares of Sarborg Limited (4.76% stake) in exchange for issuing pre-fun
Jul 31, 2026
BEARISH8-K5/10
CDT Equity Inc. filed a 1-for-10 reverse stock split to maintain compliance with Nasdaq's minimum bi
Jul 16, 2026
BEARISH8-K7/10
CDT Equity Inc. dismissed its auditor CBIZ CPAs and engaged Carr, Riggs & Ingram (CRI) as its new in
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
trading_halt
Halt Resumed: CDT — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-28T23:50:00.000Z | Resumed 2026-09-29T13:00:00.000Z
Sep 28, 2026
trading_halt
Trading Halt: CDT — T3 (News and Resumption Times)
CDT Equity Inc. Common Stock | Market: NASDAQ | Code: T3 — News and Resumption Times
Sep 28, 2026
trading_halt
Trading Halt: CDT — T1 (News Pending)
CDT Equity Inc. Common Stock | Market: NASDAQ | Code: T1 — News Pending
Sep 25, 2026
activist
CDT Equity Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that
Sep 18, 2026
contract
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own CDT (from quarterly 13F filings) and who is adding or trimming.
1 institutional holders with $10.00 total value (2 shares) as of 2026-Q1. Top holders: MORGAN.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MORGAN STANLEY | 2 | $10.00 | 100.0% | — |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
3 insiders, 17 transactions. Net -$2.9M — $0.00 bought, $2.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Regan Andrew | Chief Executive Officer | EXERCISE | 5,436,830 | $0.000100 | $543.68 |
| Aug 28, 2026 | Regan Andrew | Chief Executive Officer | SELL | 290 | — | — |
| Aug 28, 2026 | Regan Andrew | Chief Executive Officer | J | 5,436,830 | — | — |
| Jul 30, 2026 | Regan Andrew | Chief Executive Officer | J | 5,436,830 | $0.000100 | $543.68 |
| Jun 18, 2026 | Taylor Mark Andrew | 10%+ Owner | SELL | 593,289 | $1.40 | $829.1K |
| Jun 18, 2026 | Taylor Mark Andrew | 10%+ Owner | SELL | 5,000 | $0.7510 | $3.8K |
| Jun 18, 2026 | Taylor Mark Andrew | 10%+ Owner | SELL | 1,464,711 | $1.44 | $2.1M |
| Jun 18, 2026 | Taylor Mark Andrew | 10%+ Owner | SELL | 5,000 | $0.7052 | $3.5K |
| May 13, 2026 | Regan Andrew | Chief Executive Officer | AWARD | 100,000 | $1.90 | $190.0K |
| Mar 24, 2026 | Regan Andrew | Chief Executive Officer | AWARD | 147,401 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CDT.
Shares short
239,903
Settlement Sep 15, 2026
Change vs prior
+467.9%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈1.3%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 28, 2026 | T3 | Resumption Scheduled | Resumed |
| Sep 28, 2026 | T1 | News Pending | Not resumed |
| Jul 17, 2026 | T1 | News Pending | Not resumed |
| Jul 17, 2026 | T3 | Resumption Scheduled | Resumed |
All CDT filing & press-release reports (8)
- 8-K reportSep 1, 2026
- 8-K reportJul 31, 2026
- 8-K reportJul 16, 2026
- 8-K reportJul 3, 2026
- 8-K reportJun 16, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportMar 4, 2026
- 8-K reportFeb 24, 2026